Erlotinib, an orally administered EGFR inhibitor, is currently approved for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (5), but application in HNSCC was not pursued due to the poor efficacy reported by single-arm clinical trials. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.